proprietary biological, chemical, and real world patient data
wet lab experiments profiling genes and compounds
Supercomputer across any industry, BioHive-2
produced at scale, including >1T hiPSC-derived neuronal cells
gene and compound relationships profiled in our Maps
patients represented in real world patient dataset
Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to reduce the massive 90% failure rate of traditional drug discovery.
Our missionWe’re using data and AI to bring better medicines to patients, faster.
The Recursion OS has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.
We’re using data and AI to bring better medicines to patients, faster.
The Recursion OS has yielded an advanced pipeline of potential first-in-class and best-in-class treatments for conditions with high unmet need including aggressive cancers and rare diseases. Today, we’ve demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical company averages.
Our strategic partnerships allow us to accelerate the discovery of new medicines and expand our potential impact on patients.
This includes pharmaceutical partnerships with industry leaders, technology partnerships with computational titans, and next-generation data partnerships that enhance our capabilities.
Over the last decade, we have built one of the largest fit-for-purpose proprietary biological and chemical datasets in the world — 65 petabytes spanning phenomics, transcriptomics, InVivomics, proteomics, ADME, and de-identified patient data. Our automated wet lab utilizes robotics and computer vision to capture millions of cell experiments per week — enabling us to quickly make and test novel discoveries. All of our results feed back into our platform – the Recursion Operating System – in a continuously improving feedback loop.
Our data and the Recursion OS enable us to train intelligent machine learning models for drug discovery and development, which help us rapidly identify new targets and design highly optimized molecules that fuel our pipeline of potential first-in-class and best-in-class medicines.
To process all this data, we worked with NVIDIA to build biopharma’s most powerful supercomputer: BioHive-2.
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
Read more →Leveraging the Power of Patient Data in AI Drug Discovery
Read more →Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
Read more →